What are C-MYC peptides? – Myc-tag, inhibitors of MYC, research on Omomyc and limitations of scientific evidence

The term „C-MYC peptides” does not refer to a single substance. Depending on the context, it can mean short laboratory markers derived from the MYC protein, experimental peptides designed to disrupt interactions associated with MYC, or larger, modified miniproteins such as Omomyc. These materials differ in structure and purpose. The results of research on one of them cannot be attributed to the others simply because their names contain MYC. [1] [2] [3]

The article distinguishes these categories before discussing the scientific studies. The most important question concerns whether the data source describes the antibody detection reagent, the laboratory design used to study molecular mechanisms, or the therapeutic candidate being evaluated in clinical trials. Without this distinction, searching for the term „c-myc peptide” can result in confusing results.

What are C-MYC peptides? Names, synonyms, and identity

This is a particularly ambiguous term because it combines the name of a gene or protein with a broad category of molecules. The reader may encounter an epitope consisting of ten amino acid residues in an antibody catalog, a sequence designed to disrupt protein interactions, or a mini-protein studied in oncology. These are not different variants of the same material. They are distinct experimental entities that require different standards of identification, quality control, and interpretation.

This distinction is also important for indexing scientific literature. A publication mentioning the MYC pathway does not necessarily have to concern itself with research on an isolated peptide. In contrast, a study using a protein labeled with the Myc-tag may not at all analyze the biology of MYC. Therefore, literature searches should combine the name of the molecule with its intended use and, if available, the structural identifier.

MYC, c-MYC and peptide derived from MYC

MYC is the name of the gene, whereas c-MYC in the scientific literature usually refers to the corresponding protein that is a transcription factor. This protein is involved in the regulation of gene expression. However, the short fragment derived from MYC is not equivalent to the full protein. The peptide associated with MYC can be selected based on antibody recognition, participation in molecular surface interaction, or the possibility of designing an inhibitor.[1][4]

The terms „C-MYC peptide”, „MYC peptide” and „c-myc tag” can therefore appear in the same search results, even though they are not interchangeable names. Proper identification depends on the sequence, modification, design of the structure, and the method in which the material is used.

Marker for the detection of proteins and a therapeutic candidate

The well-known Myc-tag epitope is particularly useful because the presence of the tag can be verified independently of the biological function of the protein to which it has been attached. Antibody recognition depends on the availability of the epitope and the specificity of the reagent. A positive detection signal does not inform the investigator whether the attached protein is properly folded or biologically active. Conversely, a negative signal can sometimes result from the unavailability of the marker rather than a lack of protein.

The well-known Myc-tag epitope has an EQKLISEEDL sequence consisting of ten amino acid residues, and is used in protein detection methods. The experimental characterization of antibody recognition explains its usefulness as a marker. Antibody recognition of the epitope does not confirm inhibition of MYC-dependent transcription or anti-tumor activity.[2]

Omomyc belongs to a different category. It is a modified miniprotein designed to disrupt the function of MYC. The clinical candidate OMO-103 has been described as a miniprotein composed of 91 amino acids. The publication name, specific structure, and formulation identify the studied intervention more precisely than the general term „C-MYC peptide”. [5]

How are C-MYC peptides classified? Peptides, proteins, mixtures, or other substances?

The classification can be carried out by answering two separate questions: what is the chemical nature of the molecule and what function does it serve in the experiment? The first concerns the length of the amino acid chain, modifications, fusion partners, folding, and composition. The second concerns whether the molecule is a reagent for detection, a tool for experimental modification of a biological process, a delivery system, or a candidate therapeutic agent. The general terminology does not replace any of these answers.

For example, introducing the Myc epitope into an unrelated recombinant protein does not convert the entire protein into a MYC inhibitor. Similarly, a peptide fragment that alters cell behavior after binding to the transport domain does not have to retain this property as a free fragment. In both cases, the full construct is the appropriate experimental unit.

The term encompasses several molecular classes, rather than a standardized category of products. Some examples include short synthetic peptides. Others include larger polypeptides, fusion constructs, or modified mini-proteins. The preparation may also contain transport components, auxiliary substances, or attached tags.

The first category is supported by antibody and epitope studies. The others have their own literature on mechanisms and translational studies.[2][6][7][3]

The length of the chain alone is not sufficient to determine the activity of the compound. A short tag can be part of a large recombinant protein, and the transport structure may contain several functional regions. The classification should describe the entire material under study, and not just its most well-known sequence.

Small molecules that affect MYC constitute another category and should not be called peptides simply because they act on the same molecular target. Similarly, the anti-MYC antibody is a protein reagent with its own identity, and not a synonym for the peptide epitope recognized by it.

The structure and composition of C-MYC peptides – what has been established?

Structural identification should precede discussion of biological results. Reliable documentation should provide the amino acid sequence, final modifications, chemical or recombinant origin, any linker or fusion domain, and analytical evidence of identity. In the case of misfolded miniproteins, in addition to the sequence itself, conformational integrity and the integrity of the entire structure are important.

Quality measurements answer various questions. The chromatographic result can describe the components detected in the preparation, while mass spectrometry can help confirm the molecular identity. None of these methods alone proves that the intracellular inhibitor reaches the cell nucleus or that the epitope remains available after binding to another protein. Biological activity requires a separate experiment tailored to the proposed function.

Short epitope sequences

The Myc-tag sequence has been well characterized, but there are also variants and longer peptides used for immunization. A 2001 study analyzed the effect of the amino acid residues and sequence length on antibody binding. This shows that the recognition outcome depends on the specific sequence rather than on the general name of MYC.[2]

In the case of a labeled protein, the surrounding structure is also important. The location of the label, its availability, and the way it is connected can affect detection. Therefore, researchers should describe the complete fusion design and the antibody reagent used, rather than assuming that all labeled samples give the same signal.

Inhibiting peptides and fusion constructs

The architecture of fusion constructs can influence solubility, movement within cells, and the concentration of the inhibitory fragment near the intended target. Therefore, the complete construct is not simply a detail regarding how the material is prepared. When an experiment compares different transport sequences, the comparison concerns the combined intervention. It does not provide a universal estimate of the activity of the isolated fragment.

Experimental inhibitors derived from helix 1 were incorporated into polypeptide systems similar to elastin and combined with cell penetrating sequences. These structures are more complex than the free short MYC fragment. Their transport domains are part of the investigated intervention, therefore activity should not be attributed solely to the inhibitory fragment, neglecting the remaining part of the structure. [6] [7]

Omomyc and clinical material

Omomyc is a modified construct based on the region MYC responsible for dimerization and DNA binding. Its structural behavior and interactions were studied directly. A complete molecular description requires a real sequence, information about folding, purity, and method of preparation, and not a pattern adopted based on the word „MYC” alone.[4]

Therefore, there is no single molecular mass, chemical formula, or amino acid sequence that represents all „C-MYC peptides”. Offering only this broad designation leaves the identity of the substance uncertain. The appropriate approach is to obtain a specific identifier for the structure, rather than selecting any known study that appears most likely to match the claimed activity.

Studies on C-MYC peptides – evidence in humans, animals and in the laboratory

Available evidence should be organized according to the experimental question, rather than according to a hierarchy of allegedly interchangeable materials related to MYC. Antibody studies determine the properties of reagents. In vitro inhibition studies analyze molecular feasibility. Animal experiments verify biological activity in living organisms, and oncological studies assess the safety and preliminary results of a specific candidate. Each stage introduces new uncertainties, instead of automatically confirming all previous assumptions.

The term „evidence in humans” also requires caution. The OMO-103 clinical study provides direct evidence regarding this studied miniprotein in humans, but it is not direct evidence regarding the EQKLISEEDL marker or the uncharacterized product described as C-MYC peptide. Linking the result to the precisely examined material is the primary safeguard against overinterpretation.

Research on laboratory reagents

In a 1985 study, Evan and colleagues produced monoclonal antibodies using synthetic peptide immunogens derived from MYC and analyzed the recognition of the MYC protein. These were basic research studies in detection. They did not describe the administration of the MYC peptide for the treatment of cancer. [1]

Later mapping of epitopes explained the dependence of antibody recognition on sequence. These studies support the development and interpretation of tests. They are no less valuable than a therapeutic trial, but are designed to answer a different question. [2]

Experimental structures inhibiting MYC

Studies of transport structures containing helix 1 analyzed the inhibition of cell proliferation and the influence of intracellular localization. An article published in a journal in 2009, made available online in 2008, compared cell penetration sequences and showed differences in the localization and activity of individual structures. These experiments show why the delivery architecture should be considered together with the inhibitory sequence. They do not confirm efficacy in patients. [7]

Omomyc's animal studies and translational research

A 2019 study analyzed the purified Omomyc’s properties related to penetration into cells and its activity in experimental models of non-small cell lung cancer, including in in vivo studies. These studies went beyond the genetic production of the inhibitor inside cells and included testing the delivered miniprotein. The tumor results in animals supported further development, but exposure, safety, and efficacy in humans still required further investigation. [3]

Published human evidence regarding OMO-103

The number of participants is crucial for the interpretation of the study: 22 people were included in phase 1, but the reported observation of disease stabilization concerned eight of the 12 people who reached a certain assessment point after nine weeks. Disease stabilization should not be presented as a regression of the tumor or as a general rate of response. Furthermore, early studies focus on assessing the dose, safety, tolerability, and pharmacodynamic information, rather than on the final comparison of survival or quality of life with standard care.

Observations regarding the molecular target, based on biopsy analyses, provide additional mechanistic support for a particular candidate. However, they do not in themselves prove that the observed disease stabilization was caused by the intervention. The reported infusion-related reactions and dose-limiting toxicity are equally important parts of the clinical evidence and should accompany the descriptions of the initial activity.

The Phase 1 report published in 2024 included 22 people with advanced solid tumors. The primary endpoints were safety and tolerability. Among the 12 participants who reached a pre-specified assessment after nine weeks, eight were found to have disease stabilization in imaging studies. This does not mean an objective response in eight of the 22 participants. Infusion-related reactions were common, and one person experienced dose-limiting toxicity. Biopsy analyses supported the suggestion of a molecular target effect.[5]

The small, uncontrolled study design does not allow for determination of survival benefit or comparative efficacy. Disease stabilization also differs from objective tumor response. The study provides early clinical information about a specific experimental miniprotein, rather than evidence regarding general commercial „MYC peptides”.

Later recorded studies

Clinical trial registries help identify planned eligibility criteria, interventions, endpoints, and reported administrative status. However, they are not equivalent to peer-reviewed scientific results. In particular, a temporary suspension of the trial is a description of the status, not a documented explanation of its cause. Before preparing a time-dependent update, it is necessary to review the entry in the registry again, as details may change.

The official EU registry identifies the Phase 2 OMO-103 pilot study in people with advanced bone marrow cancer with a high degree of malignancy. During the review on October 23, 2026, the registry indicated a temporary suspension of the study. The registration entry confirms the study design and reported status, but does not constitute a published efficacy result. The status itself does not explain the reason for the suspension. [8]

Mechanism of action studied in the context of C-MYC peptides

Studies related to MYC encompass two fundamentally different types of molecular recognition. In antibody detection methods, the antibody recognizes a peptide epitope and generates an analytical signal. In studies on inhibition of MYC function, the modified molecule is intended to alter protein interactions, DNA-associated complexes, or further transcriptional processes. The first case confirms the interaction used in the test, while the second requires evidence of functional disruption of the biological process.

In the case of candidates acting inside the cells, demonstrating a causal relationship is particularly demanding. The material must remain intact, reach the cells, if necessary, escape the intracellular compartments where it cannot act, access the appropriate molecular location, and influence the pathway upon achieved exposure. The signal at one stage provides information, but does not replace measurements of all subsequent stages. Ultimately, clinical testing must assess results important to patients, rather than relying solely on molecular signatures.

Recognition by antibodies

In the case of an epitope peptide, the appropriate mechanism is recognition by a specific antibody. Binding can enable detection, competitive control, or other analytical applications. This mechanism is distinct from altering the biological activity of MYC within the cell.[2]

Interference with interactions related to MYC

MYC inhibitory constructs are used to study another process: disrupting the molecular interactions necessary for MYC-dependent transcription. The Omomyc studies analyzed dimer formation, interactions with MAX, and DNA binding. Mechanistic studies indicate that DNA-bound complexes, but inactive transcriptionally, are part of the inhibition model. Therefore, the mechanism should not be reduced to a universal term „MYC-blocking peptide”. [4]

Intracellular delivery and target interaction

For a candidate to act inside the cells, reaching the appropriate compartment is a fundamental research problem. Cell uptake, release from intracellular vesicles, exposure to the intact molecule, and access to the nucleus can all influence the outcome. Experiments with transport constructs show that changing the location can change the activity. [7]

The effect on the molecular target means there is evidence that the intervention affects the intended biological system. This is not equivalent to clinical benefit. The study may show the expected molecular signature, but it still requires determining whether patients live longer, function better, or experience an acceptable level of harm. Questions about clinical outcomes cannot be replaced by mechanistic measurement.

Limitations of scientific evidence regarding C-MYC peptides

An additional challenge is the variability in terminology. Terms such as „MYC inhibition”, „anti-tumor peptide”, or „cell penetration” may sound unambiguous, even though the source study measured a much narrower phenomenon. The biochemical interaction may be repeatable without demonstrating effective delivery, and the delivered construct may alter the biomarker without improving clinical outcomes. Any conclusion should correspond to the actually measured endpoint.

Another limitation concerns comparator and denominator groups. Early oncological studies often include individuals with different types of tumors and a history of prior treatment. Without a randomized control group, it is difficult to estimate the contribution of the experimental intervention to the stabilization of the disease. Presenting only the results of participants who were still available for evaluation at a later time point may also create a more favorable impression than reporting all included individuals. These problems do not invalidate the value of the Phase 1 study, but rather define the questions it can answer.

Finally, the safety conclusions relate to a specific intervention. The peptide marker used as the analytical reagent is not evaluated under the same exposure conditions as the miniprotein administered via infusion. The infusion-related reactions and dose-limiting toxicity observed in the OMO-103 study require detailed explanation, while the small sample size does not allow the characterization of rare or delayed effects. Neither the clinical study nor the widespread use of the laboratory reagent confirm the overall safety of all materials containing the MYC name.

The first limitation is the ambiguity of the categories. The literature on antibodies, markers, intracellular inhibitors, and clinical miniproteins cannot be treated as a single evidence base regarding a single substance. Before comparing the results, it is necessary to match the identities of the materials.

The second limitation is the transfer of results between models. A modified cell arrangement may produce intracellular exposure that cannot be reproduced with the supplied product. A mouse model of a tumor can provide evidence of activity, while at the same time differing from a diverse human disease. Preclinical success is the reason for further study of the candidate, not evidence of clinical efficacy.

The evidence here regarding OMO-103 in humans remains limited to early studies with a small, heterogeneous population. It does not confirm all strategies targeting MYC or show that short-term laboratory reagents derived from MYC are therapeutic agents. Later recorded studies must be evaluated based on their own results and not treated as an automatic confirmation of previous observations. [5] [8]

The molecular name itself does not confirm the quality of the product, stability, clinical usefulness, or equivalent exposure. Research materials and controlled clinical intervention differ in production and documentation. Any claim that one material inherits evidence regarding the other requires a direct assessment of identity and comparability.

Frequently asked questions about C-MYC peptides

1. Do C-MYC peptides mean one defined substance?

No. The term encompasses many research materials with different sequences and functions. The detection marker, the inhibitory fragment, and the modified miniprotein should be identified separately. [2] [3] Scientific interpretation begins with the precise design, because common terminology does not confirm that two preparations elicit the same biological effect. Therefore, a precise sequence or name of the design provides more information than the catalog title. If the source omits these details, the responsible conclusion is that the identity of the material has not been sufficiently established for comparison.

2. What do the available studies on C-MYC peptides confirm?

They confirm separate findings regarding various materials, from antibody recognition to early clinical trials of OMO-103.[1][5] These results should remain linked to the original research materials and endpoints. They do not form a general therapeutic claim regarding everything that is sold or described as a C-MYC peptide. The evidence should be grouped by function, since the validation of the reagent and clinical development do not constitute subsequent efficacy studies of a single substance. A clear summary presents each result along with the appropriate model and purpose.

3. Is Myc-tag an anti-cancer peptide?

Its confirmed use lies in its function as an in vitro laboratory detection epitope, rather than an anti-cancer agent. The recognition of a short sequence by an antibody is a different event than the inhibition of MYC activity within the cell.[2] The therapeutic claim would require independent mechanistic evidence regarding delivery and clinical studies, rather than relying on a link between the marker and the oncogen. In particular, the use of Myc-tag in a protein expression experiment does not demonstrate that the marker alters the MYC transcriptional signaling. Its confirmed value concerns analytical specificity under appropriate test conditions.

4. Is the full length of MYC the same as the peptide derived from MYC?

No. A fragment is not equivalent to the entire protein. It may retain one recognizable feature while not containing other domains or sites of interaction. The identity and function of the derived sequence must therefore be evaluated directly. Originating from a biologically important protein does not transfer all of its properties to the fragment. Even when the fragment includes a region involved in recognition or binding, the full protein may require additional domains, regulatory partners, and appropriate cellular context. Functional claims must be measured for the fragment itself.

5. Are Omomyc and OMO-103 the same substance?

OMO-103 is a clinically studied miniprotein based on Omomyc, but both terms should be used with context in mind. Omomyc also appears in preclinical studies of design and mechanisms. [3] [5] In the case of claims regarding therapeutic research, the actual clinical material is important. The broader name of the research platform does not confirm that another preparation is compatible with it. When discussing the cited human study, it is worth describing Omomyc as a research concept or a modified miniprotein platform, and OMO-103 as a clinical intervention. This avoids confusion between the biology of the design and the clinical evidence regarding the product.

6. Are all MYC inhibitors peptides?

No. The biological target does not dictate the chemical class of its inhibitors. Peptides, larger proteins, and other molecular approaches require their own identification and evidence. Calling any strategy targeting MYC a peptide obscures important differences in exposure and mechanism. The classification should be based on the actual molecule, not the pathway mentioned in the study. Searches for MYC inhibition may yield strategies based on nucleic acids, small molecules, modified proteins, and peptides. The target combines their research question but not the chemistry or clinical evidence.

7. Does inhibiting cancer cells in culture prove benefits for patients?

No. Experimental breeding does not replicate the full exposure and biological complexity of a patient’s organism. A promising result still requires confirmation of delivery, selectivity, tolerance, and clinically relevant effects. Cell-based research can support the development of a hypothesis, but its results should not be presented as proven human cancer control. Cells cultured in the laboratory may receive an experimental exposure that cannot be replicated in a tumor. Human outcomes also depend on the disease’s heterogeneity, prior treatment, and toxicity, which cannot be fully evaluated in cell culture.

8. Does reducing the tumor in mice confirm its effectiveness in humans?

No. The animal model supports evidence of preclinical activity under certain conditions. The Omomyc studies provide justification for further translational work, whereas human studies address other questions regarding safety and outcomes. [3] A credible summary indicates the model used and avoids presenting preclinical responses as the patient’s expected response. Animal models can help explain tumor exposure and biological activity in the body, but there are still differences in the biology of tumors and dosing conditions. Such results should be described as preclinical evidence for the design under study.

9. What does the stabilization of the disease mean in an early oncological study?

Stable disease means that at a given point in the assessment, neither adequate criteria of sufficient progression nor objective response have been met. It does not automatically mean a reduction in the tumor caused by treatment. In an uncontrolled study, the natural course of the disease and the selection of participants may make it difficult to assign a cause. Interpretation therefore requires knowledge of the assessment criteria, the time point, and the full number of participants. Stable disease may be clinically relevant in some situations, but this depends on the duration, the earlier rate of growth, the treatment history, and appropriate comparison. It should not be presented as a confirmed response to treatment without evidence defined in the study.

10. Why is the denominator important when presenting the results of OMO-103?

The denominator indicates which participants were included in a given result. The assessment among those who reached a later time point is not equivalent to the same result among all included participants.[5] Reports should maintain this distinction so that exclusions, early progression, or incomplete observation do not make the initial activity appear more certain than the study allows. Presenting eight of the 12 people as if they were eight of the 22 would significantly change the interpretation. Clear reporting includes the total number of participants and explains which individuals were included in each analysis.

11. Does the effect on the molecular target confirm the clinical success?

No. It confirms the evidence of biological interaction, not the final clinical outcome. A drug can affect the intended pathway without providing sufficient benefit or causing unacceptable harm. Demonstrating an effect on the target is useful for understanding the candidate and designing further studies, but the results important to patients still require separate measurement. Molecular confirmation of the pathway effect strengthens the proposed mechanism, but conclusive clinical questions concern comparative benefit, duration, quality of life, and harms. The pharmacodynamic signal does not replace all of these results.

12. Does penetration into the cells guarantee delivery to the cell nucleus?

No. Entry into the cell does not prove that the intact molecule reaches the nucleus at an effective concentration. The intracellular localization may vary between constructs, as shown by delivery systems studies. [7] It is important to distinguish uptake from access to the appropriate target compartment, rather than treating each cell signal as evidence of functional delivery. The molecule can enter the cell but remain trapped in vesicles or undergo degradation before reaching the nucleus. Therefore, localization and functional measurements are needed to confirm the intracellular mechanism.

13. Can the free blocking fragment use evidence regarding the fusion structure?

No. Coupled transport and structural elements may be necessary for the effect under investigation. Previous work related to MYC has deliberately combined inhibitory fragments with larger polypeptide systems. [6] Removal or modification of these elements creates a different intervention. Equivalence therefore requires direct testing, rather than extracting a known sequence from the original publication. Linkers, carriers, and penetrating sequences can alter exposure or stability, as well as uptake. The free fragment should be treated as a new research material until its experimental confirmation of comparability is established.

14. Does the anti-MYC antibody identify the therapeutic MYC peptide?

No. Antibody recognition identifies the available epitope under test conditions. It does not itself confirm the full sequence, chemical integrity, or therapeutic function of the material. Antibody-based detection is useful in appropriate controls, but claims of identity and activity may require additional analytical and functional measurements. Antibodies can also recognize available fragments of a larger protein or exhibit cross-reactivity under certain conditions. When a claim goes beyond simple epitope detection, independent identification methods and appropriate controls are required.

15. Does the registration of Phase 2 study prove the efficacy of the candidate?

No. Registration documents the planned study and its reported status. The entry for OMO-103 in the costochondral bone marrow is a separate source from the published phase 1 report. [8] Its mere existence does not provide data on the results, and changes in status should not be interpreted as proof of success or failure without appropriate explanations and results. Registration may take many years to precede recruitment, data collection, analysis, and publication. Status updates alone do not reveal the final balance of benefits and risks, therefore the entry should not be described as a successful clinical outcome.

16. Can the online offer of C-MYC peptide use the results of the OMO-103 study?

Not just by the common name itself. The sequence, the full structure, the formulation, the production control and the labeling all have to be comparable before a clinical study can be relevant for such a product. Even then, the limitations of the original study remain valid. Confirmatory identification does not transform preliminary evidence into a determined clinical benefit. A label that omits the sequence, modifications and production details cannot confirm that the product is Omomyc or OMO-103. Even verified chemical similarity does not automatically imply comparable clinical exposure.

17. What information should a scientific article about C-MYC peptides contain?

It should provide the exact sequence or design, modifications, delivery system, model, comparator group, and measured result. Human studies also require information about the population, observations, adverse events, and transparent denominators. These data allow the validated analytical reagent to be distinguished from the experimental inhibitor and prevent the concealment of important differences in the evidence under the broad umbrella term. In literature reviews, it is also worth noting the year of publication, the phase of the clinical trial, if applicable, funding or participation of commercial entities, and whether the results have been independently replicated. These details enable the verification of claims rather than merely repeating them.

Applications

The most justified way to interpret the claims regarding C-MYC peptides is first to identify the actual research material and then to determine the experimental system used and the endpoint measured. The EQKLISEEDL epitope has a well-established analytical function, whereas the inhibitory fragments and modified constructs have separate preclinical evidence. OMO-103 has reached clinical trials, but early clinical observations cannot be generalized to other MYC-related sequences.

In the educational research database, separating these substances improves both the scientific accuracy and the accuracy of search results. It enables people searching for antibody markers to find information about reagents without encountering unconfirmed therapeutic claims. Meanwhile, readers interested in inhibiting MYC can access specific translational studies, rather than the mixed category of unrelated peptides.

C-MYC peptides constitute a group of research materials, not a single substance with a single evidence profile. Short epitope tags have proven laboratory applications. Inhibitory constructs and mini-proteins associated with Omomyc have a separate history of mechanistic and translational research. OMO-103 has published early human data, but these remain specific to this candidate and do not confirm the activity of other products labeled with the MYC name.

Educational, medical and regulatory reservations

The article serves solely for scientific education and the critical interpretation of published research. It does not constitute medical advice, diagnosis, treatment instructions, or recommendations for the acquisition or use of substances related to MYC. The Myc-tag laboratory marker, the experimental peptide inhibitor, and the clinically studied miniprotein OMO-103 are different materials.

The results of antibody testing, cell culture studies, and tumor models in animals do not confirm safety or clinical benefits in humans. The cited Phase 1 OMO-103 study provides preliminary data on a specific intervention, but its small sample size, lack of a control group, and reported adverse events limit conclusions. Decisions regarding cancer diseases require consultation with qualified oncology specialists and consideration of treatment methods based on scientific evidence.

References

1. Evan, G. I., Lewis, G. K., Ramsay, G., & Bishop, J. M. (1985). Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Molecular and Cellular Biology, 5(12), 3610–3616. https://doi.org/10.1128/mcb.5.12.3610-3616.1985
2. Hilpert, K., Hansen, G., Wessner, H., Küttner, G., Welfle, K., Seifert, M., & Höhne, W. (2001). Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. Protein Engineering, 14(10), 803–806. https://doi.org/10.1093/protein/14.10.803
3. Beaulieu, M. E., Jauset, T., Massó-Vallés, D., Martínez-Martín, S., Rahl, P., Maltais, L., Zacarias-Fluck, M. F., Casacuberta-Serra, S., Serrano Del Pozo, E., Fiore, C., Foradada, L., Cano, V. C., Sánchez-Hervás, M., Guenther, M., Romero Sanz, E., Oteo, M., Tremblay, C., Martín, G., Letourneau, D., … Soucek, L. (2019). Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy. Science Translational Medicine, 11(484), Article eaar5012. https://doi.org/10.1126/scitranslmed.aar5012
4. Demma, M. J., Mapelli, C., Sun, A., Bodea, S., Ruprecht, B., Javaid, S., Wiswell, D., Muise, E., Chen, S., Zelina, J., Orvieto, F., Santoprete, A., Altezza, S., Tucci, F., Escandon, E., Hall, B., Ray, K., Walji, A., & O’Neil, J. (2019). Omomyc reveals new mechanisms to inhibit the MYC oncogene. Molecular and Cellular Biology, 39(22), Article e00248-19. https://doi.org/10.1128/MCB.00248-19
5. Garralda, E., Beaulieu, M. E., Moreno, V., Casacuberta-Serra, S., Martínez-Martín, S., Foradada, L., Alonso, G., Massó-Vallés, D., López-Estévez, S., Jauset, T., Corral de la Fuente, E., Doger, B., Hernández, T., Perez-Lopez, R., Arqués, O., Castillo Cano, V., Morales, J., Whitfield, J. R., Niewel, M., … Calvo, E. (2024). Targeting of MYC by OMO-103 in solid tumors: a phase 1 trial. Nature Medicine, 30(3), 762–771. https://doi.org/10.1038/s41591-024-02805-1
6. Bidwell, G. L., & Raucher, D. (2005). Application of thermally responsive polypeptides directed against c-Myc transcriptional function for cancer therapy. Molecular Cancer Therapeutics, 4(7), 1076–1085. https://doi.org/10.1158/1535-7163.MCT-04-0253
7. Bidwell, G. L., Davis, A. N., & Raucher, D. (2009). Targeting a c-Myc inhibitory polypeptide to specific intracellular compartments using cell penetrating peptides. Journal of Controlled Release, 135(1), 2–10. https://doi.org/10.1016/j.jconrel.2008.11.015
8. Vall d’Hebron Institute of Oncology. (n.d.). A phase 2 pilot study to evaluate the safety and the anti-tumour activity of the Myc inhibitor OMO-103 administered intravenously in patients with advanced high-grade osteosarcoma (EU trial 2024-510987-22-00) [Clinical trial registration]. Clinical Trials Information System. Retrieved October 23, 2026, from https://euclinicaltrials.eu/ctis-public/view/2024-510987-22-00